Tian Wenze,Wan Li,Hu Zhongwu,et al.The effect of adjuvant radiotherapy on N2 patients with non-small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2020,40(7):507-511
The effect of adjuvant radiotherapy on N2 patients with non-small cell lung cancer
Received:October 13, 2019  
DOI:10.3760/cma.j.issn.0254-5098.2020.07.003
KeyWords:Non-small cell lung cancer  Adjuvant radiotherapy  Prognosis
FundProject:
Author NameAffiliationE-mail
Tian Wenze Department of Thoracic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China  
Wan Li Department of Medical Oncology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China  
Hu Zhongwu Department of Thoracic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China  
Leng Xuechun Department of Thoracic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China  
Zhang Zhen Department of Thoracic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China  
You Zhenbing Department of Thoracic Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, 223300, China 799501150@qq.com 
Hits: 3103
Download times: 1518
Abstract::
      Objective To investigate the effect of adjuvant radiotherapy on the prognosis of patients with N2 stage non-small cell lung cancer (NSCLC) undergoing radical resection. Methods The data of 1 208 patients with NSCLC who received radical lung cancer resection combined with chemotherapy or post-operative adjuvant radiotherapy and chemotherapy from SEER database of the United States from 2004 to 2016 were included in the study. 627 patients received radical lung cancer resection combined with chemotherapy (surgery + chemotherapy group), and 581 patients received radical lung cancer resection combined with radiochemotherapy (surgery + radiochemotherapy group). We analyzed and compared the effect of postoperative adjuvant radiotherapy on the prognosis of patients with N2 stage NSCLC undergoing radical resection. The 1:1 propensity matching method was used to analyze the prognosis of the two groups. Results In the two groups of patients with stage N2 NSCLC included in the study, the median survival time was 51 months in the operation + radiotherapy and chemotherapy group, and the 3-and 5-year cancer specific survival rates were 58.3% and 44.9%, respectively. The median survival time was 50 months in operation + chemotherapy group, and the 3-and 5-year cancer specific survival rates were 59.9% and 46.5%, respectively. There was no statistically significant difference between the two groups in cancer specific survival (P>0.05). The result of subgroup analysis showed that the cancer specific survival of patients in operation + radiotherapy and chemotherapy group was significantly worse than that in operation + chemotherapy group (χ2=5.085, P<0.05). Multivariate Cox regression analysis showed that age, gender, G stage, T stage and the number of lymph node metastasis were the important factors affecting the cancer specific survival of patients with N2 NSCLC (Wald=15.236, 7.039, 4.841, 10.155, 11.192, respectively, P<0.05). After propensity matching, there was no statistically significant difference in cancer specific survival (P>0.05) between the two groups. However,in the T1 NSCLC patients, the cancer specific survival of operation + radiochemotherapy group was significantly worse than that of operation + chemotherapy group (χ2=5.364, P<0.05), while the cancer specific survival of operation + radiochemotherapy group was significantly better than that of operation + chemotherapy group in T3-4 subgroup(χ2=4.486, P<0.05). According to the tendency matching of pathological subgroups, the cancer specific survival of surgery + radiochemotherapy group was significantly better than that of surgery + chemotherapy group (χ2=6.279, P<0.05) in the non adenocarcinoma subgroup. And the multivariate Cox regression analysis indicated that postoperative radiotherapy was an important factor for cancer specific survival in patients with N2 non adenocarcinoma non-small cell lung cancer (Wald=7.300,P<0.05). However, before and after propensity matching in lung adenocarcinoma subgroup, there was no statistically significant difference in cancer specific survival between the surgery + radiochemotherapy group and the surgery + chemotherapy group (P>0.05). Conclusions Postoperative adjuvant radiotherapy can improve the prognosis of patients with T3-4 or non-adenocarcinoma N2 NSCLC. But, for other patients with N2 non-small cell lung cancer, the choice of postoperative adjuvant radiotherapy should be cautious, especially for T1 stage.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:12035936  On-line:0

v
Scan QR Code
&et=20671175A4E105EEF942BC214CF9D5F584682C344AF69B559FCD70EA1A6E943F0F7B4D868E62D60C15FBD457D0CD3F7E8618C7CBAB97A261575FACA37FE8FF9803E7C76F474350F148294C7E1246A25566829C5A6F51B4C9F7853FEB4F0E410B&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=0D1D160AB8016934&aid=1C81C91F268D76EEC9F5976CF75AB23E&vid=&iid=DF92D298D3FF1E6E&sid=B7B25E832E7F23D8&eid=B99A53AADE50D922&fileno=20200703&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="0D1D160AB8016934"; var my_aid="1C81C91F268D76EEC9F5976CF75AB23E";